<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00896493</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-16213</org_study_id>
    <secondary_id>SU-04062009-2138</secondary_id>
    <secondary_id>16213</secondary_id>
    <secondary_id>BMT206</secondary_id>
    <nct_id>NCT00896493</nct_id>
  </id_info>
  <brief_title>Ph II of Non-myeloablative Allogeneic Transplantation Using TLI &amp; ATG In Patients w/ Cutaneous T Cell Lymphoma</brief_title>
  <official_title>A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given
      that the median age at diagnosis is 55-60 years and frequently present compromised skin in
      these patients, which increases the risk of infection. Therefore, we propose a clinical study
      with allogeneic HSCT using a unique non-myeloablative preparative regimen, TLI/ATG, to treat
      advanced MF/SS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives

      -To evaluate the graft versus lymphoma effect by monitoring rate of clinical response,
      event-free and overall survival.

      Secondary Objectives

      -To evaluate the incidence and extent of acute and chronic GVHD and time to engraftment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) at 180 days</measure>
    <time_frame>180 days</time_frame>
    <description>Progression-Free Survival (PFS) will be assessed at 180 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence and extent of acute and chronic GVHD and time to engraftment.</measure>
    <time_frame>acute-first 100 days after transplant chronic-from 100days year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival (OS) is the time measurement between the day of allogeneic transplant and death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Total count of treatment related mortality will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free survival (EFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Event-free survival (EFS) is the time measurement between the day of allogeneic transplant and the first documented recurrence or death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Mycoses</condition>
  <condition>Sezary Syndrome</condition>
  <condition>Lymphoma, T-Cell, Cutaneous</condition>
  <condition>Bone Marrow Transplant Failure</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Cutaneous T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Total lymphoid irradiation &amp; anti-thymocyte immunoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TLI is administered from a 6 MeV linear accelerator in 80c- 120c Gy fractions. Anti-thymocyte-Globulin (ATG) is administered intravenously for a total dose of 7.5 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>ATG will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg</description>
    <arm_group_label>Total lymphoid irradiation &amp; anti-thymocyte immunoglobulin</arm_group_label>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>5 mg/kg PO or IV</description>
    <arm_group_label>Total lymphoid irradiation &amp; anti-thymocyte immunoglobulin</arm_group_label>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Lymphoid radiation</intervention_name>
    <description>TLI is administered ten times in 80c- 120c Gy fractions on day -11 through day -7 and day -4 through day -1</description>
    <arm_group_label>Total lymphoid irradiation &amp; anti-thymocyte immunoglobulin</arm_group_label>
    <other_name>Total lymphoid irradiation (TLI)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Stage IIB-IV mycosis fungoides or Sezary syndrome, who have failed at least 1 standard
             systemic therapy or are not candidates for standard therapy.

          2. Pathology reviewed and the diagnosis confirmed at Stanford University Medical Center.

          3. Age &gt; 18 years and &lt;= 75 years.

          4. Karnofsky Performance Status &gt;= 70%.

          5. Corrected DLCO &gt;= 40%

          6. Left ventricle ejection fraction (LVEF) &gt; 30%.

          7. ALT and AST must be &lt;= 3X normal. Total bilirubin &lt;= 3 mg/dL unless hemolysis or
             Gilbert's disease.

          8. Estimated creatinine clearance &gt;= 50 ml/min.

          9. Have a related or unrelated HLA-identical donor or one antigen/allele mismatched in
             HLA-A, B, C or DRB1.

         10. Signed informed consent.

         11. Patients with prior malignancies diagnosed &gt; 5 years ago without evidence of disease
             are eligible.

         12. Patients with a prior malignancy treated &lt; 5 years ago but have a life expectancy of &gt;
             5 years for that malignancy are eligible.

        Donor Inclusion Criteria

          1. Age &gt;=17.

          2. HIV seronegative.

          3. No contraindication to the administration of G-CSF.

          4. Willing to have a central venous catheter placed for apheresis if peripheral veins are
             inadequate

        Exclusion Criteria:

          1. Uncontrolled active infection.

          2. Uncontrolled congestive heart failure or angina.

          3. Pregnancy or nursing patients will be excluded from the study.

          4. Those who are HIV-positive will be excluded from the study due to high risk of lethal
             infection after hematopoietic cell transplantation.

        Donor Exclusion Criteria

          1. Serious medical or psychological illness.

          2. Pregnant or lactating women are not eligible

          3. Prior malignancies within the last 5 years except for non-melanoma skin cancers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Kai Weng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>May 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2009</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT00896493/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

